An article named ‘the
Future of Coverage
and
Payment
for
Personalised Medicine
and Diagnostics’ also
states the progress
personalised medicine
has made to modern
day health care. For
example, non-invasive
maternal blood testing.
In the past two years,
non-invasive prenatal
testing for trisomy disorders, such as Down’s
syndrome, has begun
to rapidly replace traditional amniocentesis methods. There
is also multi-analyte
assays with algorithms
(MAAAs). Another technological achievement
includes the development of MAAAs, which
help physicians plan
11
the management and
in many cases reduce
the overtreatment of
diseases as diverse
as breast, prostate,
colon, ovarian and thyroid cancers. Several
of these tests are
FDA approved, which
expands their potential
as widely distributed
platform-based kits.
This table below also